Actively Recruiting
Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance
Led by Nuritas Ltd · Updated on 2025-12-16
48
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
N
Nuritas Ltd
Lead Sponsor
A
Australian Catholic University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance
CONDITIONS
Official Title
Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to provide written and dated informed consent to participate in the study.
- Willing and able to comply with the protocol.
- Not taking any medication or supplements that could impact the trial as judged by the investigator or Sponsor.
- Male or female aged between 18 and 45 years with a body mass index (BMI) of 18.5 kg/m2 or greater but less than 30 kg/m2.
- Comply with American College of Sports Medicine (ACSM) guidelines for physical activity.
- Have not participated in a clinical trial within the past month and agree not to participate in another during the study.
- Agree to not significantly change diet or exercise routine during the trial.
- Willing to wear a wearable device continuously throughout the study.
You will not qualify if you...
- Known allergy or hypersensitivity to any ingredients in the investigational products.
- History of alcohol or other drug abuse in the past year.
- Performed strenuous exercise (rating of perceived exertion 13 or higher) within 48 hours before a laboratory visit.
- Consumed more than 14 alcoholic drinks per week or more than 2 drinks per day in the 48 hours before a clinic visit.
- Active smokers, nicotine users, or vaping.
- Suffering from sleep disorders or a history of clinical depression, eating disorders, or other psychiatric conditions that may affect safety or study results.
- Diagnosed with phenylketonuria or diseases affecting amino acid metabolism.
- Elevated resting heart rate over 100 beats per minute or high blood pressure (systolic over 140 mmHg or diastolic over 90 mmHg).
- Pregnant or lactating women.
- Presentation of orthostatic hypotension during screening and familiarisation visit.
- Any condition making the participant unsuitable as judged by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia, 3004
Actively Recruiting
Research Team
N
Niamh M Mohan, PhD
CONTACT
B
Brian Keogh, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here